Cytune Pharma SAS

Cytune Pharma SAS is a pioneering biotechnology startup with a focus on developing innovative immunotherapeutic agents, primarily targeting cancer. The company's flagship compound, CYP 0150, utilizes a breakthrough in immunology by harnessing an effective form of a major human immunocytokine through the trans-presentation mechanism of IL-15. Founded in 2007, the company is led by Dr. David Bechard, an experienced biotech entrepreneur, and Dr. Yannick Jacques, Director of Public Research at Inserm (National Institute for Health and Medical Research). Cytune's approach to cancer treatment involves developing conjugated monoclonal antibodies linked to CYP 0150, providing a novel and promising avenue for immunotherapy. The company has attracted significant investment, with the latest being a €6.00M Venture Round investment by the PPF Group in June 2016. By pioneering the use of interleukin-15 technology, Cytune Pharma SAS is positioned at the forefront of the biotechnology and pharmaceutical industries, offering a potentially groundbreaking solution in the field of cancer treatment through immunotherapy.